Imsidolimab (ANB019)

imsidolimab · Vanda Pharmaceuticals

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Imsidolimab (ANB019), covering 2022-03-29 to 2026-03-17. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP [Phase 3]